Ruthenium-106 Brachytherapy with or without Additional Local Therapy Shows Favorable Outcome for Variable-Sized Choroidal Melanomas in Korean Patients
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to report clinical outcomes of ruthenium-106 (106Ru) brachytherapy with or without additional local therapy for choroidal melanomas in Korean patients. Materials and Methods A total of 88 patients diagnosed with choroidal melanomas were treated with 106Ru brachytherapy between 2006 and 2012. Patients were divided into two groups according to their tumor height: a large group (! 6 mm, n=50) and a small group (< 6 mm, n=38). Most patients in the large group received combined therapy with local excision and/or transpupillary thermotherapy. In general, 85-95 Gy was administered to the apex of the tumor, while 100 Gy was administered to the point 2-6 mm from the outer surface of the sclera for patients undergoing combined therapy. Results The median follow-up duration was 30 months. The 3-year local control rate was significantly higher in the small group than in the large group (94% vs. 70%, p=0.047). The free from distant metastasis (FFDM) rate and the overall survival (OS) rate were also higher in patients in the small group (3-year FFDM, 97% vs. 76%; p=0.031 and 3-year OS, 97% vs. 72%; p=0.036). A total of 13 patients underwent enucleation. The eye-preservation rate was also higher in the small group (3-year eye-preservation rate, 94% vs. 70%; p=0.050), and tumor height was a significant prognostic factor for eye-preservation. Conclusion 106Ru brachytherapy showed favorable outcomes in small choroidal melanomas in Korean patients. Although additional local treatment could improve eye-preservation rate for large tumors, other strategies should be considered for disease control.
Abstract
Purpose The purpose of this study was to report clinical outcomes of ruthenium-106 (106Ru) brachytherapy with or without additional local therapy for choroidal melanomas in Korean patients. Materials and Methods A total of 88 patients diagnosed with choroidal melanomas were treated with 106Ru brachytherapy between 2006 and 2012. Patients were divided into two groups according to their tumor height: a large group (! 6 mm, n=50) and a small group (< 6 mm, n=38). Most patients in the large group received combined therapy with local excision and/or transpupillary thermotherapy. In general, 85-95 Gy was administered to the apex of the tumor, while 100 Gy was administered to the point 2-6 mm from the outer surface of the sclera for patients undergoing combined therapy. Results The median follow-up duration was 30 months. The 3-year local control rate was significantly higher in the small group than in the large group (94% vs. 70%, p=0.047). The free from distant metastasis (FFDM) rate and the overall survival (OS) rate were also higher in patients in the small group (3-year FFDM, 97% vs. 76%; p=0.031 and 3-year OS, 97% vs. 72%; p=0.036). A total of 13 patients underwent enucleation. The eye-preservation rate was also higher in the small group (3-year eye-preservation rate, 94% vs. 70%; p=0.050), and tumor height was a significant prognostic factor for eye-preservation. Conclusion 106Ru brachytherapy showed favorable outcomes in small choroidal melanomas in Korean patients. Although additional local treatment could improve eye-preservation rate for large tumors, other strategies should be considered for disease control.
참고문헌 (27)
- Kwon HJ, "Prognosis of choroidal melanoma and the result of ruthenium brachytherapy combined with transpupillary thermotherapy in Korean patients", Br J Ophthalmol, 97, pp.653~658 (2013)[DOI]
- Diener-West M, "The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18", Arch Ophthalmol, 119, pp.969~982 (2001)[DOI]
- Diener-West M, "The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS Report No. 17", Arch Ophthalmol, 119, pp.951~965 (2001)[DOI]
- Collaborative Ocular Melanoma Study Group, "Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study randomized trials: COMS report no. 2", Ophthalmology, 111, pp.966~976 (2004)[DOI]
- Lommatzsch PK, "Long-term followup of Ru-106", Rh-106 brachytherapy for posterior uveal melanoma, 2000, pp.238, 129~137
- Potter R, "Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: evaluation of 175 patients treated with 150 Gy from 1981-1989", Front Radiat Ther Oncol, 30, pp.143~149 (1997)
- Seregard S, "Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience", Acta Ophthalmol Scand, 75, pp.11~16 (1997)
- Shields CL, "Regression of uveal melanoma after plaque radiotherapy and thermotherapy based on chromosome 3 status", Retina, 28, pp.1289~1295 (2008)[DOI]
- Lommatzsch PK, "Optimization of irradiation time in the treatment of malignant melanoma of the choroid with beta applicators (106Ru", 106Rh), 1986, pp.189, 133~140
- Yarovoy AA, "The comparison of ruthenium brachytherapy and simultaneous transpupillary thermotherapy of choroidal melanoma with brachytherapy alone", Brachytherapy, 11, pp.224~229 (2012)[DOI]
- Shields CL, "Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients", Arch Ophthalmol, 120, pp.933~940 (2002)[DOI]
- Lommatzsch PK, "Results after beta-irradiation (106Ru", 106Rh) of choroidal melanomas: 20 years' experience, 1986, pp.70, 844~851
- Hawkins BS, "The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24", Am J Ophthalmol, 138, pp.936~951 (2004)[DOI]
- Krema H, "A comparison between 125Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma", Br J Ophthalmol, 97, pp.327~332 (2013)[DOI]
- Kaiserman N, "Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas", Br J Ophthalmol, 93, pp.1167~1171 (2009)[DOI]
- Mashayekhi A, "Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: importance of risk factors in tumor control", Ophthalmology, 122, pp.600~609 (2015)[DOI]
- Seregard S, "Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy for choroidal melanoma", Acta Ophthalmol Scand, 79, pp.19~22 (2001)[DOI]
- Kreusel KM, "Combined brachytherapy and transpupillary thermotherapy for large choroidal melanoma: tumor regression and early complications", Graefes Arch Clin Exp Ophthalmol, 244, pp.1575~1580 (2006)[DOI]
- Augsburger JJ, "Plaque radiotherapy for choroidal and ciliochoroidal melanomas with limited nodular extrascleral extension", Can J Ophthalmol, 39, pp.380~387 (2004)[DOI]
- Damato B, "Visual acuity after Ruthenium106 brachytherapy of choro-idal melanomas", Int J Radiat Oncol Biol Phys, 63, pp.392~400 (2005)[DOI]
- Verschueren KM, "Long-term outcomes of eyeconserving treatment with Ruthenium106 brachytherapy for choroidal melanoma", Radiother Oncol, 95, pp.332~338 (2010)[DOI]
- Lommatzsch PK, "Radiation effects on the optic nerve observed after brachytherapy of choroidal melanomas with 106Ru", 106Rh plaques, 1994, pp.232, 482~487
- Sakamoto T, "Histologic findings and prognosis of uveal malignant melanoma in japanese patients", Am J Ophthalmol, 121, pp.276~283 (1996)[DOI]
- Bensoussan E, "Outcomes after proton beam therapy for large choroidal melanomas in 492 Patients", Am J Ophthalmol, 165, pp.78~87 (2016)[DOI]
- Konstantinidis L, "Transpalpebral proton beam radiotherapy of choroidal melanoma", Br J Ophthalmol, 99, pp.232~235 (2015)[DOI]
- Hawkins BS, "Collaborative ocular melanoma study randomized trial of I-125 brachytherapy", Clin Trials, 8, pp.661~673 (2011)[DOI]
- Danielli R, "Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy", Cancer Immunol Immunother, 61, pp.41~48 (2012)[DOI]